Literature DB >> 14529346

Stem cell gene therapy for chronic renal failure.

T Yokoo1, K Sakurai, T Ohashi, T Kawamura.   

Abstract

Recently, stem cell research has attracted considerable attention because it could be used for the regeneration of damaged organs that are untreatable by conventional techniques, and several stem cells (or progenitor cells), such as endothelial stem cells and neural stem cells have been discovered. Following the progression of this field of research, the potential for stem cell gene therapy has increased and several therapeutic benefits have already been reported. Although this approach was originally investigated for fatal or hereditary diseases, chronic renal failure is also a candidate for stem cell gene therapy. We have proposed two different therapeutic strategies for chronic renal failure depending on whether the bone marrow stem cells differentiate and commit into mesenchymal or hematopoietic stem cells. In the case of diseases, which need reconstitution of residential renal cells, such as congenital enzyme deficiency diseases, mesenchymal stem cells should be transplanted, and in contrast, hematopoietic stem cells may be used for gene delivery for diseases, which need foreign cytokines and growth factors, such as glomerulonephritis. This article reviews the recent investigation on this tailor-made stem cell gene therapy for chronic renal failure and discusses the potential of this novel strategy and the major practical challenges of its clinical application.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529346     DOI: 10.2174/1566523034578221

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  5 in total

Review 1.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

Review 2.  Potential use of stem cells as a therapy for cystinosis.

Authors:  Celine J Rocca; Stephanie Cherqui
Journal:  Pediatr Nephrol       Date:  2018-05-22       Impact factor: 3.714

3.  Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation.

Authors:  Makoto Hagiwara; Bo Shen; Lee Chao; Julie Chao
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

4.  Mesenchymal stem cell therapy promotes the improvement and recovery of renal function in a preclinical model.

Authors:  Antônio Urt-Filho; Rodrigo Juliano Oliveira; Larissa Correa Hermeto; João Renato Pesarini; Natan de David; Wilson de Barros Cantero; Gustavo Falcão; Guido Marks; Andréia Conceição Milan Brochado Antoniolli-Silva
Journal:  Genet Mol Biol       Date:  2016-06-03       Impact factor: 1.771

5.  Kallikrein transduced mesenchymal stem cells protect against anti-GBM disease and lupus nephritis by ameliorating inflammation and oxidative stress.

Authors:  Yajuan Li; Indu Raman; Yong Du; Mei Yan; Soyoun Min; Jichen Yang; Xiangdong Fang; Wei Li; Jianxin Lu; Xin J Zhou; Chandra Mohan; Quan-Zhen Li
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.